Table 1.
The characteristics of included subjects at baseline.
| Characteristics | All participants (N, mean ± SD) | CN group (N, mean ± SD) | MCI group (N, mean ± SD) | AD group (N, mean ± SD) | P-value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 1,306 | 74.07 ± 7.16 | 374 | 74.94 ± 5.53 | 705 | 73.18 ± 7.59 | 227 | 75.40 ± 7.72 | <0.001 |
| Gender (male/female) | 1,306 | 734/572 | 374 | 188/186 | 705 | 421/284 | 227 | 125/102 | 0.011 |
| Education (years) | 1,306 | 15.80 ± 2.91 | 374 | 16.28 ± 2.71 | 705 | 15.85 ± 2.88 | 227 | 14.88 ± 3.08 | <0.001 |
| ApoE 𝜀4 (0/1/2) | 1,306 | 702/483/121 | 374 | 269/94/11 | 705 | 360/276/69 | 227 | 73/113/41 | <0.001 |
| Genotype (TT/TC+CC) | 1,306 | 648/658 | 374 | 182/192 | 705 | 353/352 | 227 | 113/114 | 0.899 |
| MMSE (scores) | 1,306 | 27.24 ± 2.57 | 374 | 29.08 ± 1.11 | 705 | 27.56 ± 1.79 | 227 | 23.24 ± 2.05 | <0.001 |
| CSF - Aβ (pg/ml) | 887 | 174.95 ± 53.67 | 252 | 199.76 ± 52.82 | 495 | 171.62 ± 51.81 | 140 | 142.06 ± 38.83 | <0.001 |
| CSF - T-tau (pg/ml) | 880 | 88.61 ± 51.76 | 251 | 69.59 ± 32.38 | 492 | 89.23 ± 53.50 | 137 | 121.25 ± 55.29 | <0.001 |
| CSF - P-tau (pg/ml) | 887 | 37.68 ± 22.00 | 252 | 30.40 ± 15.86 | 495 | 38.64 ± 22.45 | 140 | 47.40 ± 25.26 | <0.001 |
CN, cognitively normal; MCI, mild cognition impairment; AD, Alzheimer’s disease; MMSE, Mini- Mental State Examination; CSF, cerebrospinal fluid; Aβ, amyloid-β; T-tau, total tau; P-tau, phosphorylated tau. Data are given as mean ± standard deviation unless otherwise indicate. P-value indicates the value for the main effect of each subgroup (CN, MCI, and AD group), as assessed with analyses of Kruskal-Wallis rank sum test.